Patent Cliff 2026: Every Drug Losing Protection This Year
Published April 6, 2026 · USPTO patent data
2026 marks the beginning of the largest patent cliff in pharmaceutical history. An estimated $45-55 billion in annual branded drug revenue faces generic and biosimilar competition this year alone. For the pharmaceutical industry, it is a seismic shift. For patients, it is the beginning of real relief from some of the highest drug prices in the world.
The Scale of the 2026 Patent Cliff
The pharmaceutical patent cliff refers to the concentrated expiration of patent protection on blockbuster drugs that collectively generate tens of billions in annual revenue. While patent cliffs are a regular feature of the industry cycle, the 2026-2030 window is unprecedented in scale. The 2026 cohort alone represents more revenue at risk than the entire 2011-2012 cliff that saw Lipitor, Plavix, and Singulair lose protection.
What makes 2026 particularly significant is the mix of drug types losing protection. Unlike previous cliffs that were dominated by small-molecule pills, this one includes a large proportion of biologic drugs, including monoclonal antibodies and fusion proteins. These are more complex to manufacture, more difficult to copy, and represent a new frontier for biosimilar competition.
Drugs Losing Patent Protection in 2026
| Drug | Generic Name | Patents | Earliest Expiration | Strength Grade |
|---|---|---|---|---|
| Ibrance | ibrance | 19 | Aug 2026 | D |
| Herceptin | herceptin | 18 | May 2026 | D |
| Opdivo | opdivo | 15 | Apr 2026 | D |
| Enbrel | enbrel | 12 | Feb 2026 | D |
| Darzalex | darzalex | 10 | Mar 2026 | D |
| Rituxan | rituxan | 10 | Nov 2026 | D |
| Avastin | avastin | 9 | Apr 2026 | D |
| Cosentyx | cosentyx | 9 | Mar 2026 | F |
| Pomalyst | pomalyst | 8 | Jun 2026 | F |
| Xtandi | xtandi | 7 | Jun 2026 | D |
Revenue Impact by Category
The 2026 patent cliff spans multiple therapeutic categories, each with different competitive dynamics and different implications for patients and payers.
| Category | Key Drugs | Est. Revenue at Risk | Generic Competition |
|---|---|---|---|
| Immunology | Stelara, Dupixent extensions | $18-22B | Biosimilar wave expanding |
| Oncology | Keytruda, Imbruvica, Revlimid | $15-20B | Complex biosimilar + generic |
| Cardiovascular | Eliquis, Entresto | $8-10B | Small-molecule generics ready |
| Diabetes / Obesity | Trulicity, early GLP-1 patents | $4-6B | Biosimilar pipeline growing |
Company Exposure Analysis
The impact of the 2026 patent cliff is not distributed evenly across the industry. Some companies face existential revenue pressure, while others have built diversified pipelines that can absorb the loss.
- Merck: Keytruda represents over 50% of total revenue. Its patent expiration is the single largest revenue event of the entire patent cliff. Merck has been aggressively pursuing lifecycle management through subcutaneous formulations and combination therapies.
- Johnson & Johnson: Stelara is a $20B+ franchise. J&J has already begun transitioning patients to newer immunology products like Tremfya and has settled with multiple biosimilar manufacturers.
- Bristol-Myers Squibb: Eliquis and Revlimid represent the bulk of revenue. BMS faces a double patent cliff and has pursued acquisitions (Karuna, RayzeBio) to fill the gap.
- AbbVie: Though Humira biosimilars launched in 2023, AbbVie continues to face revenue erosion. The transition to Skyrizi and Rinvoq is well underway but not yet complete.
Generic Manufacturer Opportunities
For generic and biosimilar manufacturers, 2026 represents an enormous commercial opportunity. The companies best positioned to capitalize include:
- Sandoz (spun off from Novartis) — the world's largest biosimilar manufacturer with multiple candidates in late-stage development
- Teva Pharmaceutical — extensive ANDA portfolio and manufacturing capacity for small-molecule generics
- Viatris — the Mylan-Upjohn merger created a scaled generics platform with global reach
- Biocon Biologics — Indian biosimilar leader with growing US presence through partnership with Viatris
- Samsung Bioepis — backed by Samsung's manufacturing prowess with multiple approved biosimilars
What This Means for Patients
The 2026 patent cliff should ultimately result in significant savings for patients and the healthcare system. However, the benefits will arrive unevenly. Patients on small-molecule drugs like Eliquis will see generic alternatives with 80-90% lower prices relatively quickly after patent expiration. Patients on biologic drugs like Keytruda or Stelara will need to wait longer for biosimilar alternatives, and the initial price reductions will be more modest (20-40%).
The Inflation Reduction Act adds another dimension. Medicare can now negotiate prices on high-spend drugs, and several 2026 patent cliff drugs are candidates for negotiation. Even before generics arrive, negotiated Medicare prices could reduce costs for the 65+ population.
Patients should talk to their doctors and pharmacists about biosimilar substitution as options become available. Unlike small-molecule generics, which are automatically substituted at the pharmacy, biosimilar switching often requires physician involvement.
Frequently Asked Questions
Which drugs are losing patent protection in 2026?
Multiple blockbuster drugs face patent expiration in 2026, primarily in the immunology and oncology categories. The combined annual revenue of drugs losing exclusivity in 2026 exceeds $45 billion. Key drugs include several biologic treatments for autoimmune conditions, cancer immunotherapies, and specialty treatments. The exact list depends on patent litigation outcomes and any extensions granted by the FDA through pediatric exclusivity or patent term adjustments.
How much money is at risk from the 2026 patent cliff?
An estimated $45-55 billion in annual branded drug revenue is at risk from 2026 patent expirations alone. This figure represents the combined US sales of all drugs with key patents expiring this year. However, not all of this revenue will be lost immediately. Biologic drugs typically retain 60-70% of their market share in the first year of biosimilar competition, compared to small-molecule drugs which can lose 80-90% of volume within months of generic entry.
Will my medication get cheaper in 2026?
If your medication has patents expiring in 2026, you may see lower-cost alternatives become available, but the timing depends on the type of drug. For small-molecule drugs, generic versions can launch as soon as the patent expires and typically reduce prices 80-90% within two years. For biologic drugs, biosimilar alternatives take longer to develop and launch, and price reductions are more modest (30-50% over several years). Check with your pharmacist or insurer about biosimilar or generic substitution options as they become available.
Which pharmaceutical companies are most affected?
The companies most exposed to the 2026 patent cliff include those with concentrated revenue from single blockbuster products. Large pharma companies with diversified portfolios can absorb patent losses more easily, while mid-size specialty pharma companies with one or two key products face existential risk. Generic and biosimilar manufacturers like Teva, Sandoz, Viatris, and Biocon stand to benefit most as they launch competing products.
About This Data
Patent data from USPTO PatentsView API and FDA Orange Book. Revenue estimates from public financial filings and Wall Street consensus estimates. There are currently 132 patents tracked as expiring in 2026. See our methodology.